Currently, there are 449.50M common shares owned by the public and among those 440.18M shares have been available to trade.
Insiders at the company have transacted a total of 60 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 42 of these insider trades were purchases, accounting for 1,875,960 shares. Insider sales of the common stock occurred on 18 occasions, with total insider shares sold totaling 568,826 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The company’s stock has a 5-day price change of -4.45% and 15.81% over the past three months. IVZ shares are trading -12.11% year to date (YTD), with the 12-month market performance down to -22.41% lower. It has a 12-month low price of $12.48 and touched a high of $20.48 over the same period. IVZ has an average intraday trading volume of 5.68 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -6.63%, -4.09%, and 0.22% respectively.
Institutional ownership of Invesco Ltd (NYSE: IVZ) shares accounts for 84.82% of the company’s 449.50M shares outstanding.
It has a market capitalization of $7.05B and a beta (3y monthly) value of 1.45. The earnings-per-share (ttm) stands at -$0.75. The company has a debt-to-equity ratio at 0.59. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.65% over the week and 2.66% over the month.
Analysts forecast that Invesco Ltd (IVZ) will achieve an EPS of $0.38 for the current quarter, $0.4 for the next quarter and $1.9 for 2025. The lowest estimate earnings-per-share for the quarter is $0.34 while analysts give the company a high EPS estimate of $0.41. Comparatively, EPS for the current quarter was $0.38 a year ago. Earnings per share for the fiscal year are expected to increase by 11.81%, and 11.88% over the next financial year.
Looking at the support for the IVZ, a number of firms have released research notes about the stock. TD Cowen stated their Outperform rating for the stock in a research note on January 04, 2024, with the firm’s price target at $21.
